Search
Sitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnSitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsSimeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSimeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. … or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSaxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Synonyms: (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrileMixtures: KOMBIGLYZE ® XR 5 MG/ 1000 MG, Kombiglyze XR Tablet 5/500mgTezampanel
go.drugbank.com/drugs/DB06354InvestigationalTezampanel is an AMPA receptor antagonist.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingIdraparinux
go.drugbank.com/drugs/DB06406InvestigationalAs a result, Sanofi stopped the development of the drug. … Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.
Squalamine
go.drugbank.com/drugs/DB06461InvestigationalCategories: Compounds used in a research, industrial, or household settingPafuramidine
go.drugbank.com/drugs/DB06532InvestigationalPafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.